Matthew K. Fust - 17 Oct 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust
Issuer symbol
NMRA
Transactions as of
17 Oct 2024
Net transactions value
-$243,923
Form type
4
Filing time
18 Oct 2024, 18:25:19 UTC
Previous filing
20 Jun 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Options Exercise $31,475 +3,783 +19% $8.32 23,883 17 Oct 2024 Direct
transaction NMRA Common Stock Options Exercise $15,822 +1,800 +7.5% $8.79 25,683 17 Oct 2024 Direct
transaction NMRA Common Stock Options Exercise $5,433 +2,156 +8.4% $2.52 27,839 17 Oct 2024 Direct
transaction NMRA Common Stock Sale $131,643 -7,739 -28% $17.01 20,100 17 Oct 2024 Direct F1, F2
transaction NMRA Common Stock Options Exercise $54,542 +6,205 +31% $8.79 26,305 18 Oct 2024 Direct
transaction NMRA Common Stock Options Exercise $19,767 +7,844 +30% $2.52 34,149 18 Oct 2024 Direct
transaction NMRA Common Stock Sale $239,319 -14,049 -41% $17.03 20,100 18 Oct 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Options Exercise $0 -3,783 -100% $0.000000 0 17 Oct 2024 Common Stock 3,783 $8.32 Direct F4
transaction NMRA Stock Option (Right to Buy) Options Exercise $0 -1,800 -22% $0.000000 6,205 17 Oct 2024 Common Stock 1,800 $8.79 Direct F4
transaction NMRA Stock Option (Right to Buy) Options Exercise $0 -2,156 -2.3% $0.000000 93,430 17 Oct 2024 Common Stock 2,156 $2.52 Direct F4
transaction NMRA Stock Option (Right to Buy) Options Exercise $0 -6,205 -100% $0.000000 0 18 Oct 2024 Common Stock 6,205 $8.79 Direct F4
transaction NMRA Stock Option (Right to Buy) Options Exercise $0 -7,844 -8.4% $0.000000 85,586 18 Oct 2024 Common Stock 7,844 $2.52 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024.
F2 This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The shares subject to the option are fully vested and exercisable.